Healthpeak Properties vs Sabra Health Care REIT
DOC and SBRA side by side, both in miscellaneous investing. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DOC and SBRA compare
Healthpeak Properties is the larger company, worth 2.6 times as much as Sabra Health Care REIT ($14.1B against $5.4B).
On earnings, Healthpeak Properties is cheaper: it trades at 58.2× trailing earnings, against 74.9× for Sabra Health Care REIT.
Sabra Health Care REIT grew revenue faster over the last twelve months (23.4% versus 5.5% for Healthpeak Properties).
Healthpeak Properties keeps more of each dollar of sales as profit, with a net margin of 8.2% compared with 7.8% at Sabra Health Care REIT.
Both pay dividends: Healthpeak Properties yields 6.0% and Sabra Health Care REIT 5.7%.
Healthpeak Properties scores higher on the StockData Score (8 against 6 for Sabra Health Care REIT), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DOC | SBRA |
|---|---|---|
| Size and price | ||
| Market cap | $14.1B | $5.4B |
| Share price | $20.38 | $20.97 |
| Change, 1 year | 15.1% | 9.9% |
| Change, 5 years | −40.4% | 47.5% |
| Beta (5Y) | 0.71 | 0.46 |
| Employees | 411 | 58 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 4 (better) | 1 |
| Performance score | 0 | 2 (better) |
| Health score | 0 | 0 |
| Dividend score | 3 | 3 |
| Valuation | ||
| P/E | 58.2× (better) | 74.9× |
| P/S | 4.8× (better) | 5.8× |
| P/B | 1.8× (better) | 1.9× |
| EV/EBITDA | 7.5× (better) | 13.1× |
| Fair value | $16.85 | $13.09 |
| Margin of safety | −20.9% (better) | −60.2% |
| Growth | ||
| Revenue growth (TTM) | 5.5% | 23.4% (better) |
| Revenue growth, 5Y average | 11.4% (better) | 5.3% |
| Net income growth (TTM) | 47.5% (better) | −59.2% |
| EPS growth (TTM) | 45.8% (better) | −61.1% |
| EPS growth, 5Y average | −33.5% | −0.91% (better) |
| Profitability | ||
| Net margin | 8.2% (better) | 7.8% |
| Return on equity | 3.1% (better) | 2.5% |
| Financial health | ||
| Altman Z-score | 0.83 | 1.41 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 6.0% (better) | 5.7% |
| Payout ratio | 348% | 423% |
| Years of dividend growth | 1 (better) | 0 |
| Dividend growth, 5Y average | −3.8% | −2.3% (better) |
| Buyback yield | 0.72% | – |
| Shareholder yield | 6.7% (better) | 5.7% |
| Ownership | ||
| Held by institutions | 95.9% | 102% |
| Held by insiders | 0.34% | 1.9% |
| Insider net buying, 12 months | −$341K (better) | −$4.5M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 3.3% | 7.1% |
Go deeper
- DOC stock overview
- DOC income statement
- DOC valuation and score
- SBRA stock overview
- SBRA income statement
- SBRA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.